<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00156156</url>
  </required_header>
  <id_info>
    <org_study_id>A-FB04-078</org_study_id>
    <nct_id>NCT00156156</nct_id>
  </id_info>
  <brief_title>Study of Asoprisnil in the Treatment of Uterine Fibroids.</brief_title>
  <official_title>A Phase 3, Continuation Study to Evaluate the Long-Term Safety of Asoprisnil in Subjects With Uterine Leiomyomata</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the long-term safety of asoprisnil in women with
      abnormal uterine bleeding associated with uterine fibroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No medical therapy is currently available for the long-term treatment of abnormal uterine
      bleeding associated with uterine fibroids in women and many women must resort to surgery for
      relief. The objective of this study is to determine the long-term safety of two asoprisnil
      doses (10 and 25 mg tablets) administered daily to women who received asoprisnil in one of
      the asoprisnil long-term studies (study C03-062 or study M01-391). The safety endpoints for
      this study will include the affects of asoprisnil on the endometrium, ovaries, bone (a subset
      of study M01-391 subjects), lipid profiles, adverse events, and changes from baseline lab
      values and vital signs.

      Some subjects receiving asoprisnil developed endometrial changes. As a result, dosing was
      prematurely discontinued for all subjects. To ensure safety, subjects will remain on study
      and will undergo scheduled study procedures. In most subjects, endometrial changes reversed
      after asoprisnil discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term Safety.</measure>
    <time_frame>Throughout 2 year treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the monthly bleeding score and the number of days with bleeding.</measure>
    <time_frame>Each Month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemoglobin, hematocrit, TIBC, ferritin and iron concentrations.</measure>
    <time_frame>Months 3, 6, 9,12,15,18, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in volume of the largest fibroid.</measure>
    <time_frame>Months 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in bloating, pelvic pressure, dysmenorrhea and urinary symptoms.</measure>
    <time_frame>Months 6, 12, 18, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total symptom severity score and the Uterine Fibroid Symptoms-Quality of Life total score.</measure>
    <time_frame>Months 6, 12, 18, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the 8 scales of the SF-36 questionnaire.</measure>
    <time_frame>Months 6, 12, 18, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the 4 scales and overall index of the Work Limitations Questionnaire.</measure>
    <time_frame>Months 6, 12, 18, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative percent of subjects who achieve amenorrhea.</measure>
    <time_frame>Each Month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Fibroid Uterus</condition>
  <condition>Leiomyoma</condition>
  <condition>Menorrhagia</condition>
  <condition>Metrorrhagia</condition>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asoprisnil</intervention_name>
    <description>Asoprisnil 10 mg Tablet, oral Daily for up to 2 years</description>
    <arm_group_label>1</arm_group_label>
    <other_name>J867</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asoprisnil</intervention_name>
    <description>Asoprisnil 25 mg Tablet, oral Daily for up to 2 years</description>
    <arm_group_label>2</arm_group_label>
    <other_name>J867</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who have completed 12 months of active treatment in study M01-391 and Month 12
             visit procedures Or completed 18 months of active treatment in study C03-062 and Month
             18 visit procedures (with no more than a 14-day interruption in dosing from study
             C02-062 and this study) OR could not continue in a previous asoprisnil study, but are
             now eligible for retreatment

          -  Otherwise in good health

          -  Premenopausal based on Estrogen and FSH levels

          -  Adequate endometrial biopsy with no significant histological disorder

          -  Agrees to use double-barrier method of contraception

        Exclusion Criteria:

          -  Any abnormal lab or procedure result(s) the study-doctor considers important

          -  History of a blood-clotting disorder

          -  History of osteoporosis requiring treatment

          -  Any invasive procedure(s) (D&amp;C, etc) where a polyp was confirmed or a surgical or
             invasive procedure for uterine fibroids was performed during any previous asoprisnil
             study

          -  Hemoglobin &lt; 8.0 g/dL

          -  Endometrial thickness â‰¥ 19 mm
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>May 27, 2008</last_update_submitted>
  <last_update_submitted_qc>May 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Cynthia Mattia-Goldberg</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Symptomatic Uterine Fibroids</keyword>
  <keyword>Excessive Uterine Bleeding</keyword>
  <keyword>Uterine Hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Menorrhagia</mesh_term>
    <mesh_term>Metrorrhagia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

